16868253 |
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
Gilkes, AF,
Mills, KI,
Austin, SJ,
Burnett, AK,
Knapper, S,
Walsh, V
|
Blood |
2006 |
19541823 |
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation
Shimizu, M,
Ishikawa, Y,
Ishii, K,
Shiotsu, Y,
Minami, Y,
Tanizaki, R,
Akiyama, T,
Ozeki, K,
Akinaga, S,
Kanda, Y,
Mori, Y,
Umehara, H,
Kiyoi, H,
Naoe, T,
Abe, A,
Maeda, H,
Sato, Y
|
Blood |
2009 |
26108694 |
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
Shah, NP,
Stecula, A,
Smith, CC,
Sali, A,
Lin, K
|
Leukemia |
2015 |
25060518 |
FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia
Ma, HS,
Nguyen, B,
Williams, AB,
Levis, MJ,
Small, D,
Duffield, AS,
Leahy, DJ,
Brown, PA,
Galanis, A,
Li, L
|
Cancer Res. |
2014 |
19318574 |
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro
Duyster, J,
Sänger, J,
Aberg, E,
Engh, RA,
Peschel, C,
von Bubnoff, N
|
Cancer Res. |
2009 |
28576946 |
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Baer, MR,
Larrosa-Garcia, M
|
Mol. Cancer Ther. |
2017 |
23969938 |
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia
Mullighan, CG,
Baker, SD,
Rubnitz, JE,
Zimmerman, EI,
Orwick, S,
Inaba, H,
Neale, GA,
Zatechka, DS,
Buaboonnam, J,
Enemark, EJ,
Shurtleff, S,
Wang, YD,
Olsen, SR
|
Clin. Cancer Res. |
2013 |
18068628 |
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Griffin, JD,
Golub, TR,
Gilliland, DG,
Heinrich, MC,
Ebert, BL,
Stone, RM,
Jiang, J,
Schittenhelm, MM,
Berger, R,
Lee, BH,
Deininger, MW,
Teckie, S,
Döhner, K,
Loriaux, M,
Fröhling, S,
Bernard, OA,
Scholl, C,
Boggon, TJ,
Levine, RL,
Döhner, H,
Druker, BJ
|
Cancer Cell |
2007 |
15498859 |
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival
Levis, M,
Ahn, JY,
Small, D,
Lilly, M,
Kim, KT,
Meltzer, P,
Baird, K
|
Blood |
2005 |
23392356 |
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
Yu, C,
Albers, C,
Verbeek, M,
Duyster, J,
Leischner, H,
Illert, AL,
von Bubnoff, N,
Peschel, C
|
Leukemia |
2013 |
28516360 |
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Ueno, Y,
Yamada, M,
Kaneko, N,
Kuromitsu, S,
Mori, M,
Saito, R,
Shimada, I,
Mori, K,
Tanaka, R
|
Invest New Drugs |
2017 |
30651634 |
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Schlenk, RF,
Levis, MJ,
Daver, N,
Russell, NH
|
Leukemia |
2019 |
12796379 |
Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells
Schwab, R,
Spiekermann, K,
Schmieja, K,
Bagrintseva, K,
Hiddemann, W
|
Clin. Cancer Res. |
2003 |
21471285 |
The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway
Hernandez-Davies, JE,
Sakamoto, KM,
Heinrich, MC,
Tan, X,
Glaser, KB,
Landaw, EM,
Presnell, A,
Zape, JP,
Griffith, D
|
Mol. Cancer Ther. |
2011 |
12351406 |
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase
Heinrich, MC,
O'Farrell, AM,
Wait, CL,
Yee, KW,
Griffith, DJ,
McGreevey, LS,
Smolich, BD,
McMahon, G,
Cherrington, JM
|
Blood |
2002 |
22858906 |
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
Nguyen, B,
Brown, P,
Li, L,
Levis, M,
Williams, AB,
Leahy, D,
Small, D
|
Leukemia |
2013 |
29964125 |
Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases
Heinrich, MC,
Kent, JD,
Klug, LR
|
Pharmacol. Ther. |
2018 |
24227820 |
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Levis, M,
Small, D,
Cortes, J,
Ramachandran, A,
Galanis, A,
Rajkhowa, T,
Ma, H
|
Blood |
2014 |
29164965 |
The importance of FLT3 mutational analysis in acute myeloid leukemia
Patnaik, MM
|
Leuk. Lymphoma |
2018 |
32040554 |
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
Perl, AE,
Mori, K,
Hill, JE,
Tarver, TC,
Bahceci, E,
Smith, CC,
Rahmat, L
|
Blood Adv |
2020 |
24408321 |
TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo
Levis, M,
Duffield, A,
Nguyen, B,
Small, D,
Zhao, M,
Williams, A,
Greenblatt, S,
Li, L,
Rudek, M,
Ma, H
|
Blood |
2014 |